|
|
 |
|
Viewing report
|
|
|
|
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia
Frost & Sullivan, May 2010, Pages: 62
This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in Malaysia.
This Frost & Sullivan research service titled Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia provides an overview of the Hepatitis C market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians. In this research, Frost & Sullivan's expert analyst provides a list of current and pipeline products for Hepatitis C therapeutics.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Service program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
The Imminent Development and Launch of Improved Agents to Enhance Treatment Success Rates for Hepatitis C
Owing to Malaysia’s efforts to raise disease awareness, there has been a spurt in the number of Hepatitis C-diagnosed cases in the country, which, in turn, has expanded the patient pool for Hepatitis C virus (HCV) treatment. The high success rates of the current standard treatment of Pegylated Interferon and Ribavirin on Genotype 2 and 3 patients have encouraged more patients to seek this line of treatment. However, the positive patient response to the combination therapy of Pegylated Interferon and Ribavirin has been diluted by the long duration and known side effects of the treatment. “Treatment duration vary from 24 to 48 weeks, requiring weekly visits to physicians, while the side effects include bone marrow depression, flu-like symptoms, neuropsychiatric disorders, and autoimmune syndromes,” says the analyst of this research. “These factors lower patients’ compliance and sometimes result in treatment discontinuation.”
Companies that offer disease education and explore new treatments that improve efficacy and decrease side effects, which are likely to increase compliance, are very likely to succeed in the market. Refined versions of current HCV drugs, oral formulations of small molecule inhibitors, and a new drug class known as protease inhibitors are in the pipeline and represent the future of HCV treatment. Creating incentives for patients to stay the course of the current HCV treatment will increase the rates of patient compliance with the new, improved treatments. “In order to increase their HCV market share with newer drugs, companies must make sure that patients are aware of their disease status and are willing to try new treatments,” notes the analyst. “Creating marketing campaigns that highlight better efficacy, as well as partnerships with governments to lower costs and increase distribution, will enhance their market presence.”
Frost & Sullivan Growth Partnership Services
Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Hong Kong
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore
Hepatitis C Therapeutics Market—Thailand
Multi-Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in the Philippines
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in South Korea
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in China
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in India
Hepatitis C Therapeutics Market – Taiwan
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
R&D Trends: Hepatitis C
|
|
|
|
